Carbomycin

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Name
Carbomycin
Accession Number
DB11383
Type
Small Molecule
Groups
Vet approved
Description

Carbomycin, also called magnamycin, is crystalline macrolide antibiotic. This antibacterial is obtained from Streptomyces halstedii and it presents a large inhibitory effect against Gram-positive bacteria and some Mycoplasma strains. The structure of carbomycin was generated in 1957 by Robert Woodward and later modified in 1965.

Structure
Thumb
Synonyms
Not Available
External IDs
M 4209 / M-4209 / NSC-51001 / NSC-55924
Categories
UNII
AIK0XUF3AV
CAS number
Not Available
Weight
Average: 841.9785
Monoisotopic: 841.445985101
Chemical Formula
C42H67NO16
InChI Key
FQVHOULQCKDUCY-OGHXVOSASA-N
InChI
InChI=1S/C42H67NO16/c1-21(2)16-32(47)57-40-25(6)53-34(20-42(40,8)50)58-37-24(5)54-41(36(49)35(37)43(9)10)59-38-27(14-15-44)17-22(3)28(46)12-13-29-30(56-29)18-23(4)52-33(48)19-31(39(38)51-11)55-26(7)45/h12-13,15,21-25,27,29-31,34-41,49-50H,14,16-20H2,1-11H3/b13-12+/t22-,23-,24-,25+,27+,29+,30+,31-,34+,35-,36-,37-,38+,39+,40+,41+,42-/m1/s1
IUPAC Name
(2S,3S,4R,6S)-6-{[(2R,3S,4R,5R,6S)-6-{[(1S,3R,7R,8S,9S,10R,12R,14E,16S)-7-(acetyloxy)-8-methoxy-3,12-dimethyl-5,13-dioxo-10-(2-oxoethyl)-4,17-dioxabicyclo[14.1.0]heptadec-14-en-9-yl]oxy}-4-(dimethylamino)-5-hydroxy-2-methyloxan-3-yl]oxy}-4-hydroxy-2,4-dimethyloxan-3-yl 3-methylbutanoate
SMILES
[H]\C1=C([H])/[C@]2([H])O[C@@]2([H])C[C@@]([H])(C)OC(=O)C[C@@]([H])(OC(C)=O)[C@]([H])(OC)[C@@]([H])(O[C@]2([H])O[C@]([H])(C)[C@@]([H])(O[C@@]3([H])C[C@@](C)(O)[C@@]([H])(OC(=O)CC(C)C)[C@]([H])(C)O3)[C@]([H])(N(C)C)[C@@]2([H])O)[C@@]([H])(CC=O)C[C@@]([H])(C)C1=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
(R)-warfarinThe serum concentration of (R)-warfarin can be increased when it is combined with Carbomycin.
(S)-WarfarinThe serum concentration of (S)-Warfarin can be increased when it is combined with Carbomycin.
3-isobutyl-1-methyl-7H-xanthineThe metabolism of 3-isobutyl-1-methyl-7H-xanthine can be decreased when combined with Carbomycin.
4-hydroxycoumarinThe metabolism of 4-hydroxycoumarin can be decreased when combined with Carbomycin.
6-O-benzylguanineThe metabolism of 6-O-benzylguanine can be decreased when combined with Carbomycin.
7-DeazaguanineThe metabolism of 7-Deazaguanine can be decreased when combined with Carbomycin.
7,9-DimethylguanineThe metabolism of 7,9-Dimethylguanine can be decreased when combined with Carbomycin.
8-azaguanineThe metabolism of 8-azaguanine can be decreased when combined with Carbomycin.
8-chlorotheophyllineThe metabolism of 8-chlorotheophylline can be decreased when combined with Carbomycin.
9-DeazaguanineThe metabolism of 9-Deazaguanine can be decreased when combined with Carbomycin.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. HERRELL WE: Carbomycin. Int Rec Med Gen Pract Clin. 1955 Jul;168(7):463-72. [PubMed:13242215]
  2. MANNING PR, JONES PN, BIGHAM RS Jr: Clinical studies with carbomycin. N Engl J Med. 1953 Nov 5;249(19):758-61. [PubMed:13099509]
  3. Authors unspecified: MORE about carbomycin. N Engl J Med. 1953 Nov 5;249(19):784-5. [PubMed:13099516]
  4. HALLIDAY JA, ORMSBY HL: Carbomycin in ocular infections. Am J Ophthalmol. 1955 Jan;39(1):51-5. [PubMed:13218113]
  5. Ashy MA, Khalil AE, Abou-Zeid AA: Carbomycin, a macrolide antibiotic. Zentralbl Bakteriol Naturwiss. 1980;135(6):541-51. [PubMed:7006261]
  6. JUNG M: [Laboratory studies on carbomycin]. Lijec Vjesn. 1956 Mar-Apr;78(3-4):168-71. [PubMed:13399359]
  7. BERNHEIM M, JEUNE M, BETHENOD M, LEBRAT J: [Carbomycin in pediatric practice]. J Med Lyon. 1959 Feb 5;40(938):99-105. [PubMed:13631406]
  8. Authors unspecified: NEW AND nonofficial remedies: carbomycin. J Am Med Assoc. 1954 Aug 7;155(15):1335. [PubMed:13174405]
  9. HEWIT W: [Clinical and laboratory experience with carbomycin]. Dia Med. 1952 Dec 29;24(90):2335-8. [PubMed:13033598]
  10. PONS S: [Two antibiotics: magnamycin or carbomycin and tetracycline]. Minerva Med. 1955 Feb 28;46(17):567-8. [PubMed:14355928]
External Links
ChemSpider
4450165
ChEMBL
CHEMBL1231649
HET
CAI
Wikipedia
Carbomycin
PDB Entries
1k8a

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.115 mg/mLALOGPS
logP2.79ALOGPS
logP2.95ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)12.66ChemAxon
pKa (Strongest Basic)7.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area215.42 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity208.45 m3·mol-1ChemAxon
Polarizability87.34 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as aminoglycosides. These are molecules or a portion of a molecule composed of amino-modified sugars.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbohydrates and carbohydrate conjugates
Direct Parent
Aminoglycosides
Alternative Parents
O-glycosyl compounds / Disaccharides / Tricarboxylic acids and derivatives / Fatty acid esters / Oxanes / Tertiary alcohols / Alpha-hydrogen aldehydes / Trialkylamines / Secondary alcohols / 1,2-aminoalcohols
show 11 more
Substituents
Aminoglycoside core / Disaccharide / Glycosyl compound / O-glycosyl compound / Tricarboxylic acid or derivatives / Fatty acid ester / Fatty acyl / Oxane / Alpha-hydrogen aldehyde / Tertiary alcohol
show 26 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Inhibitor
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Kuper JI, D'Aprile M: Drug-Drug interactions of clinical significance in the treatment of patients with Mycobacterium avium complex disease. Clin Pharmacokinet. 2000 Sep;39(3):203-14. [PubMed:11020135]

Drug created on February 25, 2016 11:18 / Updated on June 04, 2019 07:20